AU2004279441B2 - Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia - Google Patents

Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia Download PDF

Info

Publication number
AU2004279441B2
AU2004279441B2 AU2004279441A AU2004279441A AU2004279441B2 AU 2004279441 B2 AU2004279441 B2 AU 2004279441B2 AU 2004279441 A AU2004279441 A AU 2004279441A AU 2004279441 A AU2004279441 A AU 2004279441A AU 2004279441 B2 AU2004279441 B2 AU 2004279441B2
Authority
AU
Australia
Prior art keywords
antibody
cll
chain antibody
gene
antibody gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004279441A
Other languages
English (en)
Other versions
AU2004279441A1 (en
Inventor
Emilia Albesiano
Nicholas Chiorazzi
Bradley T. Messmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Feinstein Institutes for Medical Research
Original Assignee
Feinstein Institutes for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Feinstein Institutes for Medical Research filed Critical Feinstein Institutes for Medical Research
Publication of AU2004279441A1 publication Critical patent/AU2004279441A1/en
Assigned to THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH reassignment THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH Amend patent request/document other than specification (104) Assignors: NORTH SHORE-LONG ISLAND JEWISH RESEARCH INSTITUTE
Application granted granted Critical
Publication of AU2004279441B2 publication Critical patent/AU2004279441B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
AU2004279441A 2003-10-08 2004-10-08 Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia Ceased AU2004279441B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50947303P 2003-10-08 2003-10-08
US60/509,473 2003-10-08
PCT/US2004/033176 WO2005034733A2 (en) 2003-10-08 2004-10-08 Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia

Publications (2)

Publication Number Publication Date
AU2004279441A1 AU2004279441A1 (en) 2005-04-21
AU2004279441B2 true AU2004279441B2 (en) 2010-07-01

Family

ID=34434984

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004279441A Ceased AU2004279441B2 (en) 2003-10-08 2004-10-08 Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia

Country Status (6)

Country Link
US (2) US8119340B2 (https=)
EP (1) EP1678195A4 (https=)
JP (1) JP2007510622A (https=)
AU (1) AU2004279441B2 (https=)
CA (1) CA2541360A1 (https=)
WO (1) WO2005034733A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP1678195A4 (en) 2003-10-08 2008-04-23 The Feinstein Inst Medical Res METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CHRONIC LYMPHOCYTIC B-CELL LEUKEMIA
US20070105165A1 (en) * 2005-11-04 2007-05-10 Charles Goolsby Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2576621B1 (en) * 2010-05-27 2019-04-10 Genmab A/S Monoclonal antibodies against her2
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
AU2011261396B2 (en) * 2010-06-02 2015-11-05 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
DE102012212025A1 (de) * 2012-07-10 2014-01-16 Osram Gmbh Leuchtmodul
EP2741084B1 (en) 2012-12-07 2020-01-22 AVA Lifescience GmbH Method of prognosing the clinical course of chronic lymphocytic leukemia (CLL)
CA2936092A1 (en) 2013-01-23 2014-07-31 The Board Of Trustees Of The Leland Stanford Junior University Stabilized hepatitis b core polypeptide
JP6595458B2 (ja) 2013-09-20 2019-10-23 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
EP3149167B1 (en) * 2014-05-30 2019-09-04 Academia Sinica Aptamer targeting mage-a3 peptide and uses thereof
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
EP3328994A4 (en) * 2015-07-31 2019-04-17 Memorial Sloan-Kettering Cancer Center CD56-Faced Antigen-Binding Proteins and Uses Thereof
RU2018107056A (ru) * 2015-08-24 2019-09-26 МЕДИММЬЮН, ЭлЭлСи Полипептиды mrka, антитела к ним и пути их применения
US10221249B2 (en) 2015-09-10 2019-03-05 Affigen, Llc Method of making patient specific anti-idiotype antibodies
WO2018152452A1 (en) 2017-02-17 2018-08-23 Mapp Biopharmaceutical, Inc. Monoclonal antibodies and cocktails for treatment of ebola infections
CN110678200B (zh) 2017-05-30 2024-05-17 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
ES2965352T3 (es) 2017-05-30 2024-04-12 Bristol Myers Squibb Co Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3)
CN109752548B (zh) * 2019-02-01 2022-05-06 广州金域医学检验中心有限公司 评估慢性淋巴细胞白血病预后的组合试剂及系统
EP3934418A4 (en) * 2019-03-08 2023-01-18 Memorial Sloan Kettering Cancer Center ADAM17 BINDING MOLECULES AND USES THEREOF
CN114599678A (zh) 2019-08-12 2022-06-07 希望之城 Il1rap抗体
KR20230093282A (ko) 2020-10-23 2023-06-27 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 lag-3 길항제 요법
CN113461818B (zh) * 2021-06-30 2022-01-21 徐州医科大学 靶向CD276的全人源抗体scFv、嵌合抗原受体、工程化免疫细胞及其制备方法
IL315487A (en) * 2022-03-07 2024-11-01 Agenus Inc ANTI-ILT2 antibodies and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2003086458A1 (en) * 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
EP1678195A4 (en) 2003-10-08 2008-04-23 The Feinstein Inst Medical Res METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CHRONIC LYMPHOCYTIC B-CELL LEUKEMIA

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CARTER, P., Nat. Rev. Cancer. 2001, vol. 1, no. 2, pages 118-129 (Y) *
CHIORAZZI, N. et al., Annual Review of Immunology, April 2003, vol. 21, pages 841-894 (Y) *
CHIORAZZI, N. et al., In Chronic lymphoid leukemia, 2nd Ed. B.D. Cheson, editor Marcel Dekker, New York. 2001, pages 81-109 (Y) *
DAMLE et al., Blood. 1999, Vo1.94, pages 1840-1847 (Y) *
FAIS et al., J. Clin. Invest. 1998, Vol. 102, pages 1515-1525 (Y) *
VALETTO, A . et al., Blood, 1998, vol. 92, no. 10 SUPPL. 1, PART 1-2, page 431A (Y) *

Also Published As

Publication number Publication date
US8119340B2 (en) 2012-02-21
AU2004279441A1 (en) 2005-04-21
CA2541360A1 (en) 2005-04-21
EP1678195A4 (en) 2008-04-23
WO2005034733A2 (en) 2005-04-21
US20090117095A1 (en) 2009-05-07
EP1678195A2 (en) 2006-07-12
US9745364B2 (en) 2017-08-29
US20120141462A1 (en) 2012-06-07
WO2005034733A3 (en) 2005-09-09
JP2007510622A (ja) 2007-04-26

Similar Documents

Publication Publication Date Title
AU2004279441B2 (en) Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia
Messmer et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia
Marasca et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma
Yang et al. Distinct mechanisms define murine B cell lineage immunoglobulin heavy chain (IgH) repertoires
Hardy et al. A single VH gene is utilized predominantly in anti-BrMRBC hybridomas derived from purified Ly-1 B cells. Definition of the VH11 family.
CN101668853B (zh) 癌抗原特异性t细胞受体基因、由该基因编码的肽及其使用
Bos et al. Monoclonal immunoglobulin A derived from peritoneal B cells is encoded by both germ line and somatically mutated VH genes and is reactive with commensal bacteria
CA2445989A1 (en) Colon cancer antigen panel
JPH07503062A (ja) 慢性関節リューマチの診断と治療用のＶα１２．１Ｔ細胞リセプターに特異的な試薬
Ghosh et al. In situ diversification of the antibody repertoire in chronic Lyme arthritis synovium
Feeney et al. Human cord blood kappa repertoire
US8722350B2 (en) Methods and compositions for categorizing patients
US7118912B2 (en) Methods and compositions for categorizing patients
AU2006206343A1 (en) GITR antibodies for the diagnosis of NSCLC
US5182205A (en) Nucleotide sequences which are selectively expressed in pre-B cells and probes therefor
Hadzidimitriou et al. Immunoglobulin genes in multiple myeloma: expressed and non-expressed repertoires, heavy and light chain pairings and somatic mutation patterns in a series of 101 cases
Roers et al. Single-cell PCR analysis of T helper cells in human lymph node germinal centers
Dyer et al. Unusual deletions within the immunoglobulin heavy-chain locus in acute leukemias
Smilevska et al. Immunoglobulin kappa gene repertoire and somatic hypermutation patterns in follicular lymphoma
Bende et al. Immunoglobulin diversification in B cell malignancies: internal splicing of heavy chain variable region as a by-product of somatic hypermutation
Takishita et al. Multiple myeloma: new evidence and insights from the immunoglobulin heavy chain gene and phenotypes
Li et al. Repertoire diversification in mice with an IgH-locus-targeted transgene for the rearranged VH domain of a physiologically selected anti-ssDNA antibody
US20050181370A1 (en) Cancer-associated nucleic acids and polypeptides
EP4514952A1 (en) Terminal deoxynucleotidyl transferase antibodies and uses thereof
Neubauer et al. Gastric MALT lymphoma B cells express polyreactive, somatically mutated

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH

Free format text: FORMER NAME: NORTH SHORE-LONG ISLAND JEWISH RESEARCH INSTITUTE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired